LY294002, a PI3K inhibitor, exerts its effects by curtailing AKT signaling, an alteration that may extend to the modulation of CCDC102A activity due to the protein's potential downstream positioning in this pathway. U0126, which targets MEK1/2, disrupts the MAPK/ERK pathway, a move that could reverberate through the network of proteins associated with this signaling cascade, reaching as far as CCDC102A. The JNK pathway, another node of cellular communication, is tempered by SP600125, which may recalibrate the transcriptional landscape, thus impacting proteins linked to JNK signaling, including possibly CCDC102A. Similarly, SB203580 impinges on p38 MAPK signaling, and the subsequent alterations in protein phosphorylation could ripple through to affect CCDC102A. Rapamycin, by its action on mTOR signaling, introduces changes that could cascade down to proteins under the mTOR regulatory umbrella.
Thapsigargin, by disrupting calcium homeostasis through inhibition of SERCA pumps, introduces a state of flux in calcium levels, which could perturb the function of calcium-sensitive proteins and perhaps influence CCDC102A's stability or activity. Cyclopamine, which inhibits the hedgehog pathway, and PD98059, another MEK inhibitor, both impose changes on their respective signaling routes that could extend to CCDC102A. Further exploring the cellular endomembrane system, Brefeldin A's inhibition of ARF disrupts the Golgi apparatus function, which could impinge on the activity of proteins reliant on Golgi-mediated processes, potentially including CCDC102A. W7, a calmodulin antagonist, disrupts calmodulin-dependent pathways, which could adjust the activity of calmodulin-regulated proteins, with potential consequences for CCDC102A. Gö6983's broad-spectrum inhibition of PKC could lead to a reconfiguration of PKC-mediated signaling, with possible implications for CCDC102A's role in these pathways. The modulator 2-APB, which targets inositol 1,4,5-trisphosphate receptors and store-operated calcium entry, could influence calcium signaling in a way that impacts proteins governed by calcium, among which CCDC102A may be numbered.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can alter AKT signaling, potentially affecting proteins that are regulated downstream of this pathway, including CCDC102A. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK1/2 inhibitor that can disrupt the MAPK/ERK pathway, which may modulate proteins interacting with or regulated by this pathway, possibly including CCDC102A. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could lead to altered transcription factor activity impacting proteins associated with the JNK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can change the phosphorylation status of downstream proteins, potentially affecting those associated with p38 MAPK signaling, such as CCDC102A. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can disrupt mTORC1 signaling, potentially influencing the activity of proteins that are regulated by this complex. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
An inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), disrupting calcium homeostasis, which could affect proteins sensitive to calcium levels. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
A hedgehog signaling pathway inhibitor that can modify the activity of proteins regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that can prevent the activation of the MAPK/ERK pathway, affecting the function of proteins linked to this signaling cascade. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which can disrupt Golgi apparatus function, potentially influencing the activity of proteins that rely on Golgi-mediated processes. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist that can disrupt calmodulin-dependent signaling pathways, which may in turn affect the activity of calmodulin-regulated proteins. |